专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07166452B2 Aminoketone asymmetric reductase and nucleic acid thereof 有权
标题翻译：氨基酮不对称还原酶及其核酸
公开(公告)号：US07166452B2
公开(公告)日：2007-01-23
申请号：US10469682
申请日：2002-03-01
申请人： Keiji Sakamoto , Shinji Kita , Kazuya Tsuzaki , Tadanori Morikawa , Sakayu Shimizu , Michihiko Kataoka
发明人： Keiji Sakamoto , Shinji Kita , Kazuya Tsuzaki , Tadanori Morikawa , Sakayu Shimizu , Michihiko Kataoka
IPC分类号： C12N9/02 , C12P13/00 , C12P1/06 , C12P1/04
CPC分类号： C12N9/0006 , C12P13/001 , C12P13/008
摘要： A protein, which is an aminoketone asymmetric reductase, having an effect of producing d-pseudoephedrine by acting on 1-2-methylaminopropiophenone, and having the following physiochemical properties: substrate: 1-2-methylaminopropiophenone optimum pH: pH 8.1 optimum temperature: 55° C. coenzyme: NADP molecular weight: about 28500 Da homotetramer and a nucleic acid coding the protein.
摘要翻译：作为氨基酮不对称还原酶的蛋白质，具有通过作用于1-2-甲基氨基苯丙酮而产生d-伪麻黄碱的作用，具有以下物理化学性质：底物：1-2-甲基氨基苯丙酮最适pH：pH 8.1最适温度：55 ℃。辅酶：NADP分子量：约28500Da同型四聚体和编码该蛋白质的核酸。

2. 发明授权

US06284914B1 Highly water-soluble metalloproteinase inhibitors 失效
标题翻译：高度水溶性金属蛋白酶抑制剂
公开(公告)号：US06284914B1
公开(公告)日：2001-09-04
申请号：US09492149
申请日：2000-01-27
申请人： Junko Fujisawa , Eiko Suda , Katsuhiro Igeta , Tadanori Morikawa , Tetsunori Fujisawa , Shinjiro Odake , Yasuo Morita , Tomoko Hongo , Hajime Ito
发明人： Junko Fujisawa , Eiko Suda , Katsuhiro Igeta , Tadanori Morikawa , Tetsunori Fujisawa , Shinjiro Odake , Yasuo Morita , Tomoko Hongo , Hajime Ito
IPC分类号： C07C23704
CPC分类号： C07C323/60 , A61K31/165 , C07C239/06 , C07C259/06 , C07C279/14 , C07C279/16 , C07C305/24 , C07C309/61 , C07F9/12
摘要： New compounds of general formulae (III), (IV) and (V).
摘要翻译：通式（III），（IV）和（V）的新化合物。

3. 发明授权

US6147114A Highly water-soluble metalloproteinase inhibitors 失效
标题翻译：高度水溶性金属蛋白酶抑制剂
公开(公告)号：US6147114A
公开(公告)日：2000-11-14
申请号：US945356
申请日：1997-10-24
申请人： Tetsunori Fujisawa , Shinjiro Odake , Yasuo Morita , Tomoko Hongo , Hajime Ito , Junko Yasuda , Eiko Suda , Katsuhiro Igeta , Tadanori Morikawa
发明人： Tetsunori Fujisawa , Shinjiro Odake , Yasuo Morita , Tomoko Hongo , Hajime Ito , Junko Yasuda , Eiko Suda , Katsuhiro Igeta , Tadanori Morikawa
IPC分类号： A61K31/165 , C07C239/06 , C07C259/06 , C07C279/14 , C07C279/16 , C07C305/24 , C07C309/61 , C07C323/60 , C07F9/12 , A01N37/28 , C07C239/14
CPC分类号： C07C323/60 , A61K31/165 , C07C239/06 , C07C259/06 , C07C279/14 , C07C279/16 , C07C305/24 , C07C309/61 , C07F9/12
摘要： New compounds of the general formula (I) ##STR1## (wherein R.sup.1 is a hydrogen atom, or a hydroxyl, aryl (C.sub.1 -C.sub.6)alkylene or --A--SOn--B group (A is a (C.sub.1 -C.sub.6) alkylene group; B is a (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) acyl, aryl or heterocyclyl group; n is 0, 1 or 2), R.sup.2 is a hydrogen atom, or a (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkyloxy 10 or (C.sub.1 -C.sub.6) alkylthio group, R.sup.3 and R.sup.4 are identical or different, representing a hydrogen atom, or a (C.sub.1 -C.sub.6) alkyl, aryl or aryl(C.sub.1 -C.sub.6)alkylene group, R.sup.5 is a --Y--C or C group (Y is a (C.sub.1 -C.sub.6) alkylene group, an oxygen atom, an imino group or a (C.sub.1 -C.sub.6) alkyleneimino group, C is a sulfonic acid, phosphonic acid, amidino, (C.sub.1 -C.sub.6) acyl, acylimidoyl, diphosphonomethine or dicarboxymethine group), and R.sup.6 is a hydrogen atom, or a nonsubstituted or substituted benzyl, trialkylsilyl, tert-butyldiphenylsilyl, tetrahydropyranyl or tert-butyl group) or stereoisomers thereof, and pharmaceutically acceptable salts thereof and solvates thereof, and the process for the preparation thereof, and metalloproteinase inhibitors which comprise one or more compounds selected from those compounds as effective ingredients and inhibit matrix metalloproteinases (MMPs) and/or TNF-.alpha. converting enzyme. Furthermore, the preparation intermediates to obtain the compounds of the formula (I) and the process for the preparation.
摘要翻译： PCT No.PCT / JP96 / 01135 Sec。 371 1997年10月24日第 102（e）1997年10月24日PCT PCT 1996年4月25日PCT公布。 WO96 / 33968 PCT公开号日期：1996年10月31日新化合物通式（Ⅰ）（其中R1是氢原子，或羟基，芳基（C1-C6）亚烷基或-A-SOn-B基团（A是（C1-C6）亚烷基; B是（C1-C6）烷基，（C1-C6）酰基，芳基或杂环基; n是0,1或2），R2是氢原子或（C1-C6）烷基， C1-C6）烷氧基10或（C1-C6）烷硫基，R3和R4相同或不同，代表氢原子或（C1-C6）烷基，芳基或芳基（C1-C6）亚烷基，R5是 -YC或C基（Y是（C1-C6）亚烷基，氧原子，亚氨基或（C1-C6）亚烷基亚氨基），C是磺酸，膦酸，脒基，（C1-C6 ）酰基，酰亚氨基，二亚膦酰基或二羧基甲基），R6为氢原子，或未取代或取代的苄基，三烷基甲硅烷基，叔丁基二苯基甲硅烷基，四氢吡喃基或叔丁基）或其立体异构体及其药学上可接受的盐及其溶剂合物，以及其准备过程 f和金属蛋白酶抑制剂，其包含一种或多种选自那些化合物的化合物作为有效成分并抑制基质金属蛋白酶（MMP）和/或TNF-α转化酶。此外，制备中间体以获得式（I）化合物及其制备方法。

4. 发明授权

US5880258A Anticoagulant hirudin variants and methods for their production 失效
标题翻译：抗凝血水蛭素变体及其生产方法
公开(公告)号：US5880258A
公开(公告)日：1999-03-09
申请号：US909735
申请日：1997-08-12
申请人： Ryo Muramatsu , Akiko Sukesada , Satoru Misawa , Eriko Nukui , Koichi Wada , Masaharu Nakano , Tadanori Morikawa , Kyoichi Kobashi
发明人： Ryo Muramatsu , Akiko Sukesada , Satoru Misawa , Eriko Nukui , Koichi Wada , Masaharu Nakano , Tadanori Morikawa , Kyoichi Kobashi
IPC分类号： A61K38/00 , C07K14/815 , C07K14/00
CPC分类号： C07K14/815 , A61K38/00
摘要： The present invention relates to hirudin variants having high anti-thrombin and anti-platelet activity, methods for producing them, and anti-coagulants having said variants as active ingredients.Hirudin variants shown in formula (I) having tyrosine residues or having their hydroxyl group sulfated.Methods for producing hirudin variants by sulfating hydroxyl group of said tyrosine residues, and anti-coagulants having hirudin variants shown in formula (I) as active ingredients.Phe-Glu-A-Ile-Pro-D-Tyr(R) Tyr(R) (I)�In the formula, A represents Glu or Pro, R represents Glu, Tyr (R), Glu-Asp or Glu-Tyr(R), and (R) represents the hydroxy group or its sulfated ester (--O--SO.sub.3 H) of tyrosine residue.!
摘要翻译：本发明涉及具有高抗凝血酶和抗血小板活性的水蛭素变体，其制备方法和具有所述变体作为活性成分的抗凝血剂。具有酪氨酸残基或其羟基硫酸化的式（I）所示的水蛭素变体。通过硫酸化所述酪氨酸残基的羟基来生产水蛭变异体的方法和具有式（I）所示的水蛭素变体的抗凝血剂作为活性成分。Phe-Glu-A-Ile-Pro-D-Tyr（R）Tyr ）（I）[式中，A表示Glu或Pro，R表示Glu，Tyr（R），Glu-Asp或Glu-Tyr（R），（R）表示羟基或其硫酸酯 -SO3H）酪氨酸残基。

5. 发明授权

US4086221A Polypeptides and process for producing the same 失效
标题翻译：多肽及其制备方法
公开(公告)号：US4086221A
公开(公告)日：1978-04-25
申请号：US682752
申请日：1976-05-03
申请人： Shumpei Sakakibara , Tadanori Morikawa , Eisuke Munekata , Terutoshi Kimura , Yasuo Nakagawa , Toshiharu Noda
发明人： Shumpei Sakakibara , Tadanori Morikawa , Eisuke Munekata , Terutoshi Kimura , Yasuo Nakagawa , Toshiharu Noda
IPC分类号： C07K14/575 , A61K38/00 , A61K38/23 , C07K1/113 , C07K7/56 , C07K14/585 , C07C103/52 , A61K37/00
CPC分类号： C07K14/585 , A61K38/00 , Y10S514/808
摘要： Polypeptides of the formula ##STR1## wherein A.sub.1 is Ser or Gly, A.sub.7 is Val or Met, A.sub.10 is Lys or Thr, A.sub.11 is Leu or Tyr, A.sub.12 is Ser or Thr, A.sub.14 is Glu or Asp, A.sub.15 is Leu or Phe, A.sub.16 is His or Asn, A.sub.18 is Leu or Phe, A.sub.19 is Gln or His, A.sub.21 is Tyr or Phe, A.sub.23 is Arg or Gln, A.sub.25 is Asp or Asn or Ala, A.sub.26 is Val or Thr or Ile, A.sub.28 is Ala or Ser or Val, and A.sub.30 is Thr or Val or Ala, and pharmaceutically acceptable acid addition salts and complexes, have serum calcium reducing activity.
摘要翻译：具有下式的多肽Gly-A10-A11-A12-Gln-A14-A15-A16-Lys-A18-A19-Thr-A21-Pro-A23-Thr-A25-A26-Gly-A28-Gly-A30 -Pro-NH 2其中A1是Ser或Gly，A7是Val或Met，A10是Lys或Thr，A11是Leu或Tyr，A12是Ser或Thr，A14是Glu或Asp，A15是Leu或Phe，A16是His 或Asn，A18为Leu或Phe，A19为Gln或His，A21为Tyr或Phe，A23为Arg或Gln，A25为Asp或Asn或Ala，A26为Val或Thr或Ile，A28为Ala或Ser或Val ，A30为Thr或Val或Ala，以及药学上可接受的酸加成盐和复合物具有血清钙还原活性。

6. 发明授权

US5767235A Anticoagulant hirudin variants and methods for their production 失效
标题翻译：抗凝血水蛭素变体及其生产方法
公开(公告)号：US5767235A
公开(公告)日：1998-06-16
申请号：US367758
申请日：1995-01-03
申请人： Eriko Nukui , Koichi Wada , Masaharu Nakano , Tadanori Morikawa , Kyoichi Kobashi , Ryo Muramatsu , Akiko Sukesada , Satoru Misawa
发明人： Eriko Nukui , Koichi Wada , Masaharu Nakano , Tadanori Morikawa , Kyoichi Kobashi , Ryo Muramatsu , Akiko Sukesada , Satoru Misawa
IPC分类号： A61K38/00 , C07K14/815 , A61K38/08
CPC分类号： C07K14/815 , A61K38/00
摘要： The present invention relates to hirudin variants having high anti-thrombin and anti-platelet activity, methods for producing them, and anti-coagulants having said variants as active ingredients. Hirudin variants shown in formula (I) having tyrosine residues or having their hydroxyl group sulfated. Methods for producing hirudin variants by sulfating hydroxyl group of said tyrosine residues, and anti-coagulants having hirudin variants shown in formula (I) as active ingredients. Phe-Glu-A-Ile-Pro-B-Tyr(R)-Tyr(R) (I) �In the formula, A represents Glu or Pro, B represents Glu, Tyr (R), Glu-Asp or Glu-Tyr(R), and (R) represents the hydroxy group or its sulfated ester (--O--SO.sub.3 H) of tyrosine residue.!
摘要翻译：本发明涉及具有高抗凝血酶和抗血小板活性的水蛭素变体，其制备方法和具有所述变体作为活性成分的抗凝血剂。具有酪氨酸残基或其羟基硫酸化的式（I）所示的水蛭素变体。通过将所述酪氨酸残基的羟基硫酸化制备水蛭变体的方法和具有式（I）所示水蛭素变体的抗凝血剂作为活性成分。Phe-Glu-A-Ile-Pro-B-Tyr（R）-Tyr R）（I）[式中，A表示Glu或Pro，B表示Glu，Tyr（R），Glu-Asp或Glu-Tyr（R），（R）表示羟基或其硫酸酯（ - O-SO3H）酪氨酸残基。

7. 发明授权

US3988309A EEL calcitonin 失效
标题翻译： EEL降钙素
公开(公告)号：US3988309A
公开(公告)日：1976-10-26
申请号：US536889
申请日：1974-12-17
申请人： Tetsuo Matsuda , Susumu Watanabe , Shunpei Sakakibara , Eisuke Munekata , Tadanori Morikawa , Masaru Otani , Toshiharu Noda , Hirose Yamauchi , Tosio Meguro , Shuichi Kitazawa
发明人： Tetsuo Matsuda , Susumu Watanabe , Shunpei Sakakibara , Eisuke Munekata , Tadanori Morikawa , Masaru Otani , Toshiharu Noda , Hirose Yamauchi , Tosio Meguro , Shuichi Kitazawa
IPC分类号： A61K38/00 , C07K14/585 , C07C103/52 , C07G7/00
CPC分类号： C07K14/585 , A61K38/00 , Y10S514/808 , Y10S530/857
摘要： A polypeptide having calcitonin activity of the formula ##EQU1## and the salts thereof with pharmaceutically acceptable acids.
摘要翻译：具有式H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val -Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln- Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ala-Gly-Thr-Pro-NH 2及其盐与药学上可接受的酸。

8. 发明授权

US06835559B2 Process for the production of optically active &bgr;-amino alcohols 失效
标题翻译：光学活性β-氨基醇的制备方法
公开(公告)号：US06835559B2
公开(公告)日：2004-12-28
申请号：US10240056
申请日：2003-01-22
申请人： Keiji Sakamoto , Shinji Kita , Kazuya Tsuzaki , Tadanori Morikawa , Sakayu Shimizu , Michihiko Kataoka
发明人： Keiji Sakamoto , Shinji Kita , Kazuya Tsuzaki , Tadanori Morikawa , Sakayu Shimizu , Michihiko Kataoka
IPC分类号： C12P1300
CPC分类号： C12P13/001 , C12P13/008 , C12P41/002 , Y10S435/822 , Y10S435/865 , Y10S435/877 , Y10S435/911 , Y10S435/914 , Y10S435/917 , Y10S435/918
摘要： A process for producing an optical active &bgr;-amino alcohol, the method comprising the step of allowing at least one microorganism selected from the group consisting of microorganisms belonging to the genus Morganella and others, to act on an enantiomeric mixture of an &agr;-aminoketone or a salt thereof having the general formula (I): to produce an optical active &bgr;-amino alcohol with the desired optical activity having the general formula (II) described below in a high yield as well as in a highly selective manner:
摘要翻译：一种制备光学活性β-氨基醇的方法，所述方法包括允许至少一种选自属于摩根氏菌属和其他微生物的微生物的微生物作用于α-氨基酮或其对映异构体混合物其具有通式（I）的盐：以高产率和高度选择性的方式制备具有下述通式（II）的具有所需光学活性的光学活性β-氨基醇：

9. 发明授权

US5100874A Hydroxamic acid tetrapeptide derivatives 失效
标题翻译：羟基四氢吡啶衍生物
公开(公告)号：US5100874A
公开(公告)日：1992-03-31
申请号：US392931
申请日：1989-08-04
申请人： Shinjiro Odake , Toru Okayama , Masami Obata , Tadanori Morikawa , Yutaka Nagai
发明人： Shinjiro Odake , Toru Okayama , Masami Obata , Tadanori Morikawa , Yutaka Nagai
IPC分类号： C12N9/99 , A61K38/55 , A61P29/00 , C07K5/02 , C07K5/10 , C07K5/103
CPC分类号： C07K5/1008 , C07K5/0202 , Y02P20/55
摘要： New peptide derivatives of which utility in the treatment of such diseases as rheumatoid arthritis, peridental diseases, corneal ulcer and epidermolysis bullosa is expected. These compounds are hydroxamic acid derivatives of tetrapeptides having a specific inhibitory activity against collagenase derived from vertebrates.
摘要翻译： PCT No.PCT / JP88 / 01281 Sec。 371日期1989年8月4日 102（e）日期1989年8月4日PCT提交1988年12月16日PCT公布。第WO89 / 05819号公报日期：1989年6月29日。预计可用于治疗诸如类风湿性关节炎，意外疾病，角膜溃疡和大疱性表皮松解症等疾病的新型肽衍生物。这些化合物是对衍生自脊椎动物的胶原酶具有特异性抑制活性的四肽的异羟肟酸衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式